Study ID: TV48125-CNS-30051 | 2015-004550-18

Study Title

Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

Teva Identifier

TV48125-CNS-30051 | 2015-004550-18

ClinicalTrials.gov Identifier

NCT02638103

Study Status

Completed

Trial Condition(s)

Migraine

Interventions

Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 70 Years

Trial Duration

February 26, 2016 - December 8, 2018

Phase

Phase 3

Study Type

Interventional